News
ESPR
2.500
-0.40%
-0.010
Weekly Report: what happened at ESPR last week (0708-0712)?
Weekly Report · 9h ago
Weekly Report: what happened at ESPR last week (0701-0705)?
Weekly Report · 07/08 11:50
Weekly Report: what happened at ESPR last week (0624-0628)?
Weekly Report · 07/01 11:51
Notable analyst calls this week: Nike, Micron and FedEx among top picks
The S&P500 closed in the red on Friday after an eventful week on Wall Street. Nike, Micron and FedEx posted strong quarterly results. The Nasdaq advanced over 2% and the Dow dropped 0.6% for the week. The market was also focused on the first U.S. Presidential debate.
Seeking Alpha · 06/29 18:31
Esperion Therapeutics Price Target Maintained With a $8.00/Share by Needham
Dow Jones · 06/28 17:43
Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target
Benzinga · 06/28 17:32
Optimizing Cash Flow and Market Potential: A Buy Rating for Esperion
TipRanks · 06/28 17:25
Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 06/28 15:18
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Benzinga · 06/28 15:08
Esperion’s Strategic Financial Moves and Regulatory Successes Prompt a Buy Rating
TipRanks · 06/28 14:35
Esperion Secures Funding and Clears Debt through Royalty Deal
TipRanks · 06/28 12:28
Esperion Shares Rise on Monetization of European Royalties
Dow Jones · 06/28 12:23
ESPERION THERAPEUTICS INC: OMERS LIFE SCIENCES TO PURCHASE ESPERION'S EUROPEAN ROYALTY ON BEMPEDOIC ACID PRODUCTS FOR $304.7 MLN
Reuters · 06/28 11:00
ESPERION THERAPEUTICS INC: ESPERION RETAINS RIGHTS TO RECEIVE ALL POTENTIAL FUTURE MILESTONES OF UP TO $300 MLN
Reuters · 06/28 11:00
ESPERION THERAPEUTICS INC - OMERS TO RECEIVE 15-25% OF NET BEMPEDOIC ACID SALES IN EUROPE
Reuters · 06/28 11:00
ESPERION ANNOUNCES MONETIZATION OF EUROPEAN ROYALTIES AND CONCURRENT PAYOFF AND TERMINATION OF EXISTING REVENUE INTEREST FACILITY
Reuters · 06/28 11:00
Weekly Report: what happened at ESPR last week (0617-0621)?
Weekly Report · 06/24 12:00
Esperion closes down 16% following BofA downgrade
Seeking Alpha · 06/20 20:10
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. Fell 7.8% to $116.37 on Thursday. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down 20.2% year-on-year. MGO Global, Inc. Shares jumped 222.8%.
Benzinga · 06/20 17:26
Esperion Therapeutics Shares Fall After BofA Downgrade
Dow Jones · 06/20 16:41
More
Webull provides a variety of real-time ESPR stock news. You can receive the latest news about Esperion Therape through multiple platforms. This information may help you make smarter investment decisions.
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.